Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 168 results for fibrosis

  1. Board, executive team and senior leaders interests register

    Outside interests of the NICE board

  2. Highly specialised technologies evaluation committee members

    Biographies for each member of the highly specialised technologies evaluation committee.

  3. OxyMask for delivering oxygen therapy (MIB160)

    NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy .

    Medtech innovation briefing
    Published
    27 September 2018

  4. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

    Evidence summary
    Published
    22 December 2015

  5. Diabetic retinopathy: management and monitoring (NG242)

    This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.

    NICE guideline
    Published
    13 August 2024
    View recommendations

    Sections for NG242

  6. Otitis media (acute): antimicrobial prescribing (NG91)

    This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be caused by viruses or bacteria. It lasts for about a week, and most children get better in 3 days without antibiotics. Serious complications are rare.

    Antimicrobial prescribing guideline
    Last updated
    11 March 2022
    View recommendations

    Sections for NG91

  7. Cystic fibrosis: long-term azithromycin (ESUOM37)

    This evidence summary has been updated and replaced by NICE guideline NG78.

    Withdrawn advice

  8. Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Withdrawn advice

  9. Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Withdrawn advice

  10. Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Withdrawn advice

  11. Sofosbuvir for treating chronic hepatitis C (TA330)

    Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)

    Technology appraisal guidance
    Published
    25 February 2015
    View recommendations

    Sections for TA330

  12. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

    This guidance has been updated and replaced by NICE technology appraisal guidance 988.

    Withdrawn guidance

  13. The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs (MIB159)

    NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .

    Medtech innovation briefing
    Published
    14 September 2018

  14. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued Reference number: GID-HST10007

    Highly specialised technologies guidance
    Discontinued

  15. Idebenone for treating Duchenne muscular dystrophy [ID1092]

    Discontinued Reference number: GID-TA10310

    Technology appraisal guidance
    Discontinued